FDA committee recommends EUA for Novavax’s COVID-19 vaccine

An FDA advisory committee on Tuesday recommended that Novavax’s two-dose COVID-19 vaccine be made available in the United States under an emergency use authorization.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21-0, with one abstention, to recommend the adjuvanted, recombinant spike protein nanoparticle vaccine for anyone aged 18 years or older, saying the benefits of the vaccine outweigh its risks.
The vote came more than 4 months after Novavax asked the FDA to consider the protein-based vaccine for an EUA, and after WHO issued two emergency use

An FDA advisory committee on Tuesday recommended that Novavax’s two-dose COVID-19 vaccine be made available in the United States under an emergency use authorization.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21-0, with one abstention, to recommend the adjuvanted, recombinant spike protein nanoparticle vaccine for anyone aged 18 years or older, saying the benefits of the vaccine outweigh its risks.
The vote came more than 4 months after Novavax asked the FDA to consider the protein-based vaccine for an EUA, and after WHO issued two emergency use